- S-1 plus cisplatin versus fluorouracil plus cisplatin in advanced gastric or gastro-esophageal junction adenocarcinoma patients: a pilot studyLi Yuhong; Qiu Miaozhen; Xu Jianming; Sun Guoping; Lu Huishan; Liu Yunpeng; Zhong Meizuo; Zhang Helong; Yu Shiying; Li Wei; Hu Xiaohua; Wang Jiejun; Cheng Ying; Zhou Juntian; Guo Zengqing; Guan Zhongzhen; Xu RuihuaONCOTARGET, 2015, 6(33): 35107-35115.
- Comparative effectiveness and safety between oxaliplatin-based and cisplatin-based therapy in advanced gastric cancer: A meta-analysis of randomized controlled trialsHuang Jun; Zhao Yongzhao; Xu Yong; Zhu Yanjie; Huang Jiale; Liu Yanna; Zhao Liying; Li Zhijia; Liu Hao; Wang Qi long; Qi XiaolongONCOTARGET, 2016, 7(23): 34824-34831.
- The efficacy and safety of S-1-based regimens in the first-line treatment of advanced gastric cancer: a systematic review and meta-analysister Veer Emil; Mohammad Nadia Haj; Lodder Paul; Ngai Lok Lam; Samaan Mary; van Oijen Martijn G H; van Laarhoven Hanneke W MGastric Cancer, 2016, 19(3): 696-712.
期刊论文
Non-platinum-based chemotherapy for treatment of advanced gastric cancer: 5-fluorouracil, taxanes, and irinotecan
5阅读
